The first poster presentation includes the results of studies investigating the use of a cathepsin S
inhibitor in an experimental model of Alzheimer's Disease.
and LEO Pharma A/S today announced that their collaboration on the development of an oral treatment for psoriasis has reached an important milestone as Virobay has now initiated a Phase 1 clinical trial of VBY-891 - a selective cathepsin S
The methods depend upon inhibiting invariant chain proteolysis by cathepsin S
from class II MHC/invariant chain complexes, thereby reducing the competency of class II MHC molecules for binding antigenic peptides, reducing presentation of antigenic peptides by class II MHC molecules, and suppressing immune responses.
Celera Genomics (NYSE:CRA), an Applera Corporation business, today announced that Schering AG has acquired its cathepsin S
inhibitor small molecule drug program for the treatment of autoimmune diseases.
today announced that their development of an oral treatment for pain has reached an important milestone, as Virobay has now initiated a Phase 1 clinical trial of VBY-036 - a selective cathepsin S
Medivir acquired all product rights to the Cathepsin S
Inflammation - Cathepsin S
/K In diseases like osteoarthritis or rheumatoid arthritis, the protein expression of Cathepsin S
and K is found to be a key driver for chronic inflammation and tissue remodeling.
STOCKHOLM, Sweden -- Medivir AB, a publicly traded pharmaceutical company based in Sweden and UK, has acquired all project rights for the development of Cathepsin S
inhibitors from its former world-wide partner Peptimmune Inc.
The cathepsin S
project, directed to autoimmune disorders, has recently developed compounds which are superior to the previously designated Candidate Drug, CD-1.
Studies with cathepsin S
inhibitors have demonstrated a reduction in the perception of pain (nociception) in animals, with no sedating effects, suggesting a role for cathepsin S
in neuropathic and inflammatory pain.
Celera Genomics (NYSE:CRA), an Applera Corporation business, today announced the initiation of Phase I clinical testing for its cathepsin S
inhibitor, CRA-028129, for the treatment of psoriasis.
The recent milestone payment was triggered by J&JPRD's selection of a compound targeting the Cathepsin S
enzyme as a development candidate.